VISTAGEN THERAP. DL-,001 WKN: A2AJU8 ISIN: US92840H2022 Forum: Aktien Thema: Hauptdiskussion

https://www.businesswire.com/news/home/20230606005568/en/Vistagen-Announces-Stockholder-Approved-Reverse-Stock-Split

☕️

https://www.marketscreener.com/amp/quote/stock/VISTAGEN-THERAPEUTICS-IN-27506590/news/Vistagen-to-Present-Fasedienol-PH94B-Safety-and-Exploratory-Efficacy-Data-from-Phase-3-Open-Label-43992841/

🎈

https://www.businesswire.com/news/home/20230406005269/en/Vistagen-Receives-New-European-Patent-for-AV-101

https://www.businesswire.com/news/home/20230330005332/en/FDA-Provides-Positive-Feedback-to-Vistagen-Regarding-Use-of-the-Liebowitz-Social-Anxiety-Scale-LSAS-as-an-Endpoint-in-Phase-3-Development-of-Fasedienol-PH94B-for-Treatment-of-Social-Anxiety-Disorder

Yessss....Du warst schneller.

https://www.vistagen.com/news/press-releases/

Vistagen gibt positive Daten in einer offenen Phase-3-Studie mit Fasedienol (PH94B) bei Erwachsenen mit sozialer Angststörung bekannt https://www.businesswire.com/news/home/20230322005351/en/Vistagen-Announces-Positive-Data-in-Fasedienol-PH94B-Phase-3-Open-Label-Study-in-Adults-with-Social-Anxiety-Disorder

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder https://www.vistagen.com/news-releases/news-release-details/vistagen-announces-completion-last-patient-last-visit-phase-1 U.S. Phase 1 study with newly optimized formulation intended to facilitate Phase 2B development of itruvone as a stand-alone treatment of major depressive disorder Top line results anticipated in Q2 2023

https://kalkinemedia.com/us/amp/business-news/pharma/brief-vistagen-therapeutics-on-march-7-received-letter-from-nasdaq-that-co-granted-until-sept-5-2023-to-regain-compliance-with-min-bid-price-requirement

https://seekingalpha.com/news/3943768-vistagen-readies-12m-share-secondary-offering VistaGen readies 12M-share secondary offering • VistaGen (NASDAQ:VTGN) down 4.3% premarket after filing a prospectus to sell 12.4M common shares by selling stockholders. • The company will not receive any proceeds from the sale of the shares offered. • This prospectus does not necessarily mean that the selling stockholders will offer or sell those shares. • Recently, VTGN secured new U.S. patent for PH80 nasal spray for migraine.

VistaGen Therapeutics (VTGN) Announces 12.41M Share Offering ... https://www.streetinsider.com/dr/news.php?id=21318243

https://www.streetinsider.com/dr/news.php?id=21304145&gfv=1

Bissel Bewegung zum Feierabend 🍀

Nach der letzten Welle jetzt misstrauisch.... eigentlich jetzt Kursziel 1 Dollar....bis Juni, July....